Want to join the conversation?
On completion of the Stemcentrx acquisition, $ABBV intends to execute an accelerated share repurchase program of up to $4Bil of the company's common stock. Company expects the deal to reduce EPS by about $0.20 in 2016, with addition to EPS beginning in 2020. $ABBV is updating its 2016 adjusted diluted EPS outlook to $4.62-4.82.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.